



Rejuvenation Field Technology Magnetic Aligned Plasma Natural Pain Relief, Longevity and Reduction of Degenerative Disease

INTRODUCTION

Rejuvenation Field Technology (RFT) is an innovative company at the leading edge in research and development of frequency modulated electromagnetic healing waveforms applied to living organisms.

With a foundation of decades of research, RFT has harnessed the precise frequencies (IP) and hardware (IP) for the production of "Biologically Active Fields", which have been proven to have medical applications. The use of electromagnetic waves for therapy has been well documented for over 60 years.

Our unique, novel and patentable technology may have an influence on pain reduction, restoring coherence in single and multicellular organisms thereby increasing longevity, enhancing immune systems, reducing healing times and lowering dependence on pharmaceutical drugs, with the potential of restoring homeostasis in cases of degenerative diseases including cancer.

Our Mission is to study the potential of these bio-active fields and the validity of entering into the market place with a proven, scientifically validated bio-active field generating device, which assists in natural healing abilities of the human body. The adoption of the RFT will enable various caregiver industries, hospitals, clinics, spas and private individuals to have an economical therapeutic technology readily available.

Stage 1 of development would consist of completion of prototype (currently 80% complete) and initial validation of bioactive field.

Stage 2 of development would consist of a group of contracted third party individuals and or organizations to validate and verify the rejuvenative effects of the device.

Stage 3 would be marketing and distribution.

Stage 4 of development would consist of FDA trials for the efficacy of such a device while exploring market potential in the US while simultaneously preparing for market penetration into other countries.

We are committed to educate the world on the environmental, economic and healing potential of our unique technology.

BACKGROUND

In thousands of animal experiments in France in the 1960s and '70s, Antoine Prioré used scalar electromagnetics to cure terminal cancers, infectious diseases, and

restore suppressed immune systems. Government funding was cancelled in 1974, and the technology was suppressed.

However, the influence of magnetic and electric fields on organs, tissues, and cells has been further investigated during the past 30 years [Ottani et al., 1988; King, 1999; Funk et al., 2009]. EMF is reported to influence a wide variety of biological systems such as bone, skin and hematologic. For example, several in vitro studies have suggested that EMF affects the cellular physiology of many types of human cells [Masiuk et al., 2008; Sullivan et al., 2011]. In physical medicine, particularly, low frequency EMF has been applied clinically for early healing of wounds and certain musculocutaneous and musculotendinous lesions. However, most of these clinical studies are based on experience rather than scientific evidence.

Recent protocols based on electromagnetic fields have been developed as non-surgical and minimally invasive treatments of tumors. In particular, short electric pulses can induce important non-thermal changes in cell physiology, especially the permeability of the cell membrane. Including the unique ability to selectively kill tumor cells without harming normal surrounding tissue.

Nanosecond, high-voltage electric pulses (nsEP) induce permeabilization of the plasma membrane and the membranes of cell organelles, leading to various responses in cells including cytochrome c release from mitochondria and caspase activation associated with apoptosis [T.B. Napotnik et al, 2012].

Tom Bearden places 20 years of research into the Public Domain to stimulate redevelopment of scalar EM healing (the "Porthole Process"). Application of the "Porthole Process" can potentially cure cancer, AIDS, SARS, anthrax, or ANY cellular affliction in 30-second treatment. Genetic diseases can be similarly treatable.

Further material on the background to this technology is available at the end of this document.

PROBLEMS AND BUSINESS OPPORTUNITY

Many people are now looking for alternative methods of treatment that do not use the harmful effects of chemotherapy, radiation and pharmaceutical drugs. A Regenerative Field Device is not only feasible with today's technology, but would be in high demand by a public that is moving away from isolated chemical-based healing methodologies. Ideally the device would have little or no side effects, as opposed to the pharmaceutical approach with its many debilitating, health-compromising side effects.

Natural and alternative cancer cures are immensely popular. This is largely due to the failure and expense of conventional cancer treatments. Numerous studies question the value of mainstream medical cancer treatments, and cancer is one of the diseases that mainstream medicine indeed has trouble handling, but however is extremely lucrative in the sales of chemotherapy, as Tom Bearden is quoted, "\$250,000 on the hoof for every patient." Multiplied by several million, we see the resistance to the threat to their profit margin.

We consider the present moment to be the right time to advance this unique technology, with modern societies eager to adapt new technologies and the added advancements in our understanding of biological effects of electrotherapies, we feel the acceptance of our work will be in our favor.

KEY FEATURES

- Solid-State nonlinear materials are used. This allows for an increase of at least one order of magnitude for power density, and tighter control for frequency and phase coherence.
- An increase of phase coherence allows for the inclusion of different waveforms, which can conceivably "steer" the probabilities into a past for the organism to a state better than it started with. This is necessary, as in some genetic conditions, a chronological "map" results that means that the same condition will recur over time. In order to prevent this, one must rewrite the "map", and restructure those probabilities. This is true regeneration, in which the organism changes to a less entropic state that will not be repeated in the future, similar to what some simpler organisms, such as jellyfish, do, which are in a state of virtual immortality.
- Patentable new technology for non-invasive pain relief, free of side effects that can be used continuously to target pain throughout the body. Based on magnetic cascade, which eliminates pain and speeds healing.
- This device utilizes new principles which correctly impedance match external pulsed magnetic fields to non-invasively correct neuronal and other biological informational channels to reduce and eliminate pain.
- Cutting edge technology for Longevity Science, Natural Pain Relief, Deep Rejuvenation of Human Cells (possibly including Stem cells) and a overall broad spectrum of frequencies that are used for a variety of ailments
- Extensive preliminary evidence that PHASE CONJUGATE MAGNETICS can not only reduce pain but also increase healing rate. We understand the physics- because this creates the magnetic environment of restored fractality- precisely the definition of healing in biologic tissue.

Mitigation of age-related diseases may also be possible, and life extension as a result of this. **A WORLD FIRST!**

WHAT DOES OUR TECHNOLOGY DO?

MAGNETIC PHASE CONJUGATION is a magnetic cascade, which eliminates pain and speeds healing. Our frequencies applied to our magnetic field, produces an implosion of self-organizing biological fields. What this means is we now know precisely the magnetic and dielectric fields which restores compression and is the FIELD SYMMETRY KEY to healing and tissue regeneration. There are many other uses such as bone regeneration and stem cell switching.

APPLICATIONS

- Pain reduction (as both Priore and Rauscher showed)
- Swelling reduction
- Wound regeneration
- Cancer remission (well documented by Priore and the French authorities)
- Switching on and off - stem cell de-differentiation
- Reducing the effects of aging (time reversal in phase conjugate optics was real as long as the past being reverted to was a MORE ordered state)

We will also be documenting the effect of the phase conjugate regenerative field on the collagen cross binding which is so critical to the aging process.

OUR ADVANTAGES:

- Original Priore technology used plasmas for mixing: highly inefficient. Only 1% of energy is emitted as longitudinal components.
- This technology had a low power density: Magnetically activated plasmas take up a large volume, and the tube that Priore was intending to use took up a large fraction of the building.
- Cost: The original Priore plasma tubes were heavy and labor intensive to construct, with mercury vapor and noble gases. The major expenses were the

tubes and drivers. In this new version, the solid-state emitters/mixers are a fraction of that cost, and robust enough to carry into the field, without the fragility of noble gas tubes. New solid-state VLSI (Very Large Scale Integration) devices promise to shrink the physical volume and production costs even further.

We have also shown the frequency signature in EKG power spectra (which correlates to increased DNA braid density) makes a strong reason to believe that the phase conjugate process associated with EEG / EKG frequency signatures is actually a piezo trigger for the macromolecular programming of DNA by recursive piezoelectric induced braiding coherence (when the thread embeds in the string embeds in the rope (all by coherent embedding)). The result is DNA programming by active site alignment. This all points back to the power of a low frequency phase conjugate pump wave (like Priore used) to actually effect DNA by aligning active sites.

The commercial implications of this are striking and include:

- Sports medicine
- Military medicine
- Addressing stubborn wounds to heal
- Almost any situation required biologically regeneration / order increase.

REVENUE STREAMS

- Sales of RFT directly into marketplace
- Spa and clinics are set up to house the device in prominent locations
- Hospitals
- Licensing fees from partners

INVESTMENT ROLLOUT

RFT is currently seeking visionary aware investors to help us realize our goal of delivering our technology at a competitive price. Seed capital is necessary for advancing this forward.

As an investor in RFT, you will play a crucial role in:

- Supporting an alternative treatment for pain relief and serious ailments
- Pioneering a new paradigm for the treatment of degenerative diseases
- Leaving a legacy that improves the lives of millions of people

The market potential for natural healing approach to a broad spectrum of ailments is huge!

Start up seed capital, is required to enter into full operational business development. This prototype is used as the template for further development and serves as a functioning working example and demo unit.

Current Status

Dan Winter developed a new equation based on precise negentropic phase conjugate centripetal force, down to the Planck time/distance, which actually predicted the core frequencies Priore used. This gives us the breakthrough to base our technology advance on hard physics and validated science (and not speculation). Paul Harris is in the process of constructing a preliminary prototype in Calgary, which is unfinished and requiring further funding. Further development includes the single carrier wave capable of modulating complex wave forms creating multiple RF induced fields mixed in the ion plasma tube – referred to as “the conjugator”. Various gases and frequency cascades were experimented with. Field already appears to be bioactive at this early stage; quite noticeable results have been an observation of reduction in inflammation and accelerated healing of wound on one hand.

Stage 2 Budget

Based on proving the effect of the generated bioactive field. This requires various consultants and independent validations and analysis with small trial runs.

Manufacturing protocols and costing are completely worked out

Timeline 6-12 months

Stage 3 Budget

Business Development plan written and market penetration starts. A clinic is set up for clients to come and use the technology and this acts as a demonstration unit that can be used for sales. Media attention starts.

Stage 4 Budget

FDA trials begin.

On completion a multi million-dollar market opens up with hospitals and other caregiver industries.

TECHNOLOGY BENCHMARKS

Phase 1: In Vitro Testing

In this stage, we begin with two small plasma tubes approximately 1 cm long and 2 mm in diameter that can be placed easily on either side of a microscope slide or petri dish. 20 controls and 20 active samples are used for a useful sigma to compute efficacy. 20 of the samples are treated with UV or gamma irradiation to induce genetic damage. Biological samples are selected with a known genome for efficient identification of the process. Analysis is done with dark field microscopy as well to observe morphological changes during the treatment process. Once efficacy is determined to be positive, the next phase is initiated.

Phase 2: In Vivo Testing

Now we test with autonomous multicellular organisms using the same sigma: 20 controls and 20 active samples. More than likely an insect species with a short life and well-known genome is selected, such as drosophila. The same UV or gamma irradiation is used with the samples, and treatment with the plasma tubes is done. In this instance, an array of smaller tubes is used to produce the desired effect modulated with the same key signatures as the in vitro testing. Tissue samples are analyzed under dark field for morphological changes, and efficacy determined. Genetic sequencing is done to determine changes on the molecular and quantum level. Once this round of testing is complete, it is time to move to mammal testing.

Phase 3: In Vivo Testing, Small Mammal

This round will use the same sigma and scaled up tubes for mice. We will be at the level that Priore had attained in the 1970's with mammal testing. The difference of course will be that instead of the ridiculous requirements that were placed on Priore, we will be using sensible ones to more efficiently use our resources of time and funding with the same previous number of 20 controls and 20 active samples. Priore used tissue implantation for cancer induction as well as different chemical toxins to test the recovery time of the animals. This may also be done to repeat his work for correlative purposes. Once the correlation is performed between the past and present work, then another stage can be done: comparative genomic analyses. This was not possible in Priore's day, and telomeres were also not considered, or collagen cross bonding, which is an indication of biological aging. Thus a more complete analysis can be done to prove the PCR causative aspects of the device. Once efficacy has been determined, then it is time to move on to the next phase.

Phase 4: In Vivo Testing, Large Mammal

Once again, the plasma treatment tubes or PCR crystal array is scaled up to the size of large mammals such as farm animals and horses. A strategic alliance is formed



with 20 veterinary clients, and two from each are selected for either control or sample groups. NDA and non-comp documents are secured. Once again, genomic and dark-field microscopy is used for determining efficacy, and analyses done. In this stage, it is for real-world evaluation of known disease conditions, and deliberate controlled toxin introduction to the system is omitted, as enough data has been collected with the previous phases. This phase may take more time due to the longer life expectancy of the animals in the longevity study. When this is done, then it's on to the next phase.

Phase 5: In Vivo Testing, Human

Proper scaling is done for the phased array so that a patient can be placed comfortably on a bed surrounded by the active elements of the machine. Due to the placebo effect, a second such machine is constructed without the driving signatures, and a study is done between the two and the control group not receiving treatment. This will require a double-blind study where the operators are not aware of the operating principle of the machine so as to not influence the test results. Once again, dark field and genomic analyses are done, and efficacy evaluated. This completes the explanation of the test phases.

Variations

Signatures may be fine-tuned and variants made through the phases to optimize the effect. Once this is done, then signature "overlays" can be tested for the mitigation of pre-existing genetic damage. This has already been performed on GMO corn as well as other organisms. We know that legacy DNA exists in various species tracking evolutionary development, and in some birth defects this is seen as reptilian scales in mammals and tails in humans. In this case, the reversion has gone too far back, and can be mitigated using the correct overlay to flip the proper genetic switches. In Bearden's provisional patent, a reference is made to this possible overlay or superimposition of another signature to avoid genetic expression in the future of the organism, so that if there is a genetic tendency to neurological or tissue disorders in a specific time frame, one can "steer" the future expression away from those disorders. In this case, genetic inheritance would no longer carry a death sentence.



Background

Pain has been relieved by electricity since ancient times, at first by means of applying live electric fish to the tender areas to cause numbness. But once frictional

machines were found to produce electro-static electricity (Franklinism) in the mid 18th century the use of living organisms was discontinued.

By the late 18th century Galvani had discovered the fact that frog muscle tissue responded to electrical currents however he believed the electricity came from the tissue. Volta discovered a chemical means of producing electricity from the first form of battery or voltaic pile after repeating Galvani's experiments in order to show that the muscle twitching response was due to an external source of electrical current. This discovery led to the medical use of direct current (Galvanism). Its ability to cause necrosis by electrolytic means was employed in the destruction of tumors in early years. This was through the production of sodium hydroxide in the electrolytic process.

Galvanism was also applied to needles, hence the first form of electroacupuncture pioneered by Berlioz and Sarlandière. When the needles were inserted into hair follicles, it was found that through the electrolysis of saline that the production of sodium hydroxide would cause necrosis of the hair root. This is still being used today as a cure for hirsutism, or excessive hair growth, known as the "Wolf Man Syndrome". For the first time the combination of electrotherapy and oriental ideas about needling were brought together. Furthermore these early experimenters showed how stimulation of the nervous system brought profound relief from pain. In the early 19th century Faraday's work on the production of alternating currents and his understanding of electrolysis provided medicine with advancement from these early forms of Galvanism.

A variety of safer alternating and interrupted currents (Faradism) have been employed in electrotherapy ever since, particularly in the form of electroacupuncture, TENS (Transcutaneous Electrical Neural Stimulation) and Dorsal Column Stimulation. The popularity of electrotherapy fell during the early part of the 20th century as no one knew how its effects were obtained. However now we know how different nerve fibers respond to different frequencies and amplitudes, and electrotherapy permits the modern practitioner to stimulate the nervous system in a number of different ways to induce the selective production of various monoamines, amino acids and peptides in the central nervous system.

During this down period of electrotherapy, two notable investigators experienced success in their experiments, only to have their life's work ridiculed, destroyed ultimately suppressed, Royal Raymond Rife and Antoine Prioré.

Rife was a San Diego scientist who during the 1930s, invented a powerful optical microscope in order to be able to see living bacteria, viruses and fungi (pathogens) that he suspected to be causing a range of illnesses. He found he could see the individual pathogens better by illuminating them with a light frequency that matched their own resonance frequency and causing them to glow. When he intensified the frequencies, he observed the pathogens either bursting or going inanimate. This led him to create an RF driven tube 'beam ray' device that could weaken or destroy various pathogens by energetically exciting destructive resonances in their constituent chemicals. Rife's claims were ultimately discredited by the medical profession in the 1950s from pressures arising from the growing pharmaceutical industry and their ties to the FDA. He died in 1971, penniless and embittered by the failure of his devices to garner scientific acceptance.

Later, thousands of animal experiments in France in the 1960s and '70s, Antoine Prioré used what is now called scalar electromagnetics to cure terminal cancers, infectious diseases, and restore suppressed immune systems. Government funding was canceled in 1974, and the technology was again suppressed, due to the same mechanisms as in the US.

However, the influence of magnetic and electric fields on organs, tissues, and cells has been further investigated during the past 30 years [Ottani et al., 1988; King, 1999; Funk et al., 2009]. EMF is reported to influence a wide variety of biological systems such as bone, skin and hematologic. For example, several in vitro studies have suggested that EMF affects the cellular physiology of many types of human cells [Masiuk et al., 2008; Sullivan et al., 2011]. In physical medicine, particularly, low frequency EMF has been applied clinically for early healing of wounds and certain musculocutaneous and musculotendinous lesions. However, most of these clinical studies are based on experience rather than scientific evidence.

Recent protocols based on electromagnetic fields have been developed as non-surgical and minimally invasive treatments of tumors. In particular, short electric pulses can induce important non-thermal changes in cell physiology, especially the permeability of the cell membrane. Including the unique ability to selectively kill tumor cells without harming normal surrounding tissue.

Nanosecond, high-voltage electric pulses (nsEP) induce permeabilization of the plasma membrane and the membranes of cell organelles, leading to various responses in cells including cytochrome c release from mitochondria and caspase activation associated with apoptosis. {cite}

RECENT BACKGROUND

This is a tentative protocol for test and evaluation of next generation breakthrough "Conjugate Rejuvenation Fields" based on a new understanding of concepts pioneered by Antoine Priore in the 1970's. Much of what we learned about the system had to be reconstructed from fragments of accounts from various individuals, as the inventor had passed on. Another complication was that the inventor himself did not have a clear understanding of the method of operation of the machine, and put it together as most inventors' do: on a purely intuitive level.

Thomas Bearden arrived on the scene somewhat late in the game, but Priore was still alive at that time, and still engaged in a legal and ethical fight with the French medical establishment, who considered his machine to be unpopular and a threat to the profit margin of the pharmaceutical industry, as it still does today.

Bearden arrived at a working theory for the machine and published this in his provisional patent in 2001 (available upon request). This theory involved something he termed "the porthole concept"--the idea that mitogenic radiation, primarily in the UV region of the spectrum but also involving other frequencies, carry information about the quantum state of the point of emission. Using phase conjugation, Tesla's "Invisible Wire", we can phase lock into the wave emitted, and change the quantum state at the point of emission.

Since the phase conjugate replica (PCR) wave has negative entropy (this is substantiated in the publications of Pepper and others), it can reverse active entropic states seen as disease in the organism. The PCR wave can also carry information into the cell nucleus that was not there originally, and do correction on inherited genetic damage, thus reversing birth defects. This takes much longer than surgery, of course, as the new tissue conforms to the morphology of the corrected genetic structure. Once the organism is finished with it's reconfiguration, the condition is permanent unless another signature is needed to "tweak" the structure. Thus the horrible birth defects caused by radiation and chemical damage can be corrected.

Initial tests with PCR irradiation of GMO corn shows this is possible, and the artificial genetic modifications were reversed back to normal. Priore also noted that mice that were treated seemed more youthful. If the genetic damage theory of aging is correct, then the PCR would also correct for the distorted standing wave signatures

that occur over time. Pepper noted that when an image of a cat was passed through frosted glass to deliberately introduce entropic distortion, and that image went through a phase conjugate mirror, the resultant image showed the original image of the cat minus the distortion. PCR devices are currently being used to correct for phase distortion in fiber optic communication lines for this same reason.

Therefore it is not unreasonable to assume that we are looking at a regenerative effect induced through the phase coupling of the Priore device, as plasmas are known phase conjugators and transducers of transverse into longitudinal waves.

Further background material can be read at <http://breakthru-technologies.com/technologies/magnetically-activated-plasmas-map>

Additional Background:

Tesla's contribution in the late 1890's was profound. He hypothesized that electronic waves produced by lightning discharges could have significant benefits for human health. He developed the Tesla-coil and "magnifying transmitter" to excite the atmosphere into producing the unique energy structure of natural lightning; and, part showman, Tesla often engaged in sensational personal demonstrations of electrical phenomena to illustrate his ability to harness its energy safely. In a more advanced and important refinement, Tesla constructed an impulse-stimulated magnifying coil system with an elliptically shaped output terminal to selectively generate negative ions, which he determined to be best suited for electrotherapy.

Tesla maintained that these blue light streams and radio frequency (RF) electronic wave therapy in general could, in principle, make it possible to minimize aging and disease.

A decade or so later Georges Lakhovsky, a Russian physicist living in France, employed Tesla-coil electrotherapy in successful treatments of plants and patients with cancers. With some assistance from Tesla's publications, Lakhovsky designed and manufactured his own multi-wave 'Tesla coils' and, by 1925, wrote one of the first books on this subject: *The Secret of Life*. Its third edition cites numerous case studies in Italian, French, English and American hospitals.

About this time, another important, though seemingly unrelated, advance was the pioneering work in cell biology of the Russian histologist, Dr. Alexander Gurwitsch. In the early 1920s, Gurwitsch discovered the "mitogenic" wave communication of vital information exchanged between living- cells with bio photons. Gurwitsch coined the term mitogenic, using as root-words "mitos," meaning thread, and "genic," meaning caused by a gene, to identify the vital nature of these inter-cell communications. His experiments showed that ordinary (non-quartz) glass could prevent living cells from exchanging such vital information, explaining the later remarkable success of Dr. Raymond Rife's tuned-light, biophoton approach to electro medicine, described below.

In 1932, Tesla's noninvasive electrotherapy was publicly acclaimed before the American Congress of Physical Therapy. At a 1932 New York City seminar, Dr. Gustave Kolischer announced:

"Tesla's high-frequency electrical currents are bringing about highly beneficial results in dealing with cancer, surpassing anything that could be accomplished with ordinary surgery.

Not long after this, Dr. Royal Raymond Rife, a research physician at the University of California at Riverside in the 1930's, took up the clinical torch. Claims by Lakhovsky and others of astounding medical cures attributable to Tesla's noninvasive electrotherapy intrigued Rife. As a physician and scientist, Rife reasoned that specific disease pathogens could be identified by their unique resonant response to a variable-wavelength light source. To test this thesis, he invented a device he called the "Universal Microscope," which itself provided insight as to the central role of the light spectrum of electromagnetic energy in living tissues and disease. He used this device to conduct microscopic studies of a patient's living blood and or diseased tissue cultures, before and after treatment. The 1944 Annual Report of the Smithsonian Institution published a brief description of how Rife's Universal Microscope worked:

"Between the source of light and the specimen are subtended two circular, wedge-shaped, block crystal quartz prisms for the purpose of polarizing the light passing through the specimen, polarization being the practical application of the theory that light waves vibrate in all planes perpendicular to the direction in which they are propagated. ...Now, when the portion of the spectrum is reached in which both the organism and the color band vibrate in exact accord, one with the other, a definite characteristic spectrum is emitted by the organism. ...The virus of the *Bacillus thypous* is always turquoise blue, the *Bacillus coil* always mahogany colored, the *Mycobacterium laprae* always a ruby shade, the filter-passing form or virus of tuberculosis is always emerald green, the virus of cancer a purplish red, and so on.

The first clinical work demonstrating the efficacy of Rife's system in the treatment of cancer was completed under the supervision of Milbank Johnson, M.D., which was setup under a special Medical Research Committee of the University of Southern California. 16 cases were treated at the clinic for many types of malignancy. After 3 months, 14 of these so-called hopeless cases were signed off as clinically cured by the staff of five medical doctors and Dr. Alvin G. Foord M.D. Pathologist for the group.

This concludes the background.

Further background information can be read at
<http://breakthru-technologies.com/technologies/magnetically-activated-plasmas-map>



Contact
Roger Green
ecoglobalfuels@earthlink.net
Phone 1-848 702 3779
www.Breakthru-Technologies.com